Late-breaking trials of PCR Tokyo Valves 2026

This session presents pivotal late-breaking trials from PCR Tokyo Valves 2026, offering one-year outcomes and real-world experiences in transcatheter valve therapies. Highlights include the AltaValve early feasibility study on atrial fixation TMVR, invasive registry insights on prosthesis-patient mismatch post-TAVR, and registry data on tricuspid and mitral transcatheter edge-to-edge repair in Asia. Additionally, temporal trends from the OCEAN-TAVI registry provide valuable perspectives on early outcomes after transcatheter aortic valve implantation.